UK – NICE backs NHS use of Bayer’s Vitrakvi via the CDF

Bayer's Vitrakvi (larotrectinib) will be available via the NHS in England and Wales to treat a variety of cancers.

The drug is a histology independent cancer treatment that targets all solid tumours with a certain genetic mutation (the NTRK gene fusion), regardless of where the primary tumour is in the body.

The National Institute for Health and Care Excellence has approved NHS funding for the drug via the Cancer Drugs Fund.

This positive recommendation is a change to the initial decision where the price of Vitrakvi was too high to be considered cost-effective, while NICE also felt that there was to much uncertainty in the clinical evidence as it had not been compared with other treatments…